
|Videos|March 28, 2019
Dr. Fleming Shares Encouraging Data With Antiandrogen Therapies in Prostate Cancer
Author(s)Mark T. Fleming, MD
Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, The US Oncology Research, discusses exciting data seen with antiandrogen agents for the treatment of prostate cancer.
Advertisement
Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, The US Oncology Research, discusses exciting data seen with antiandrogen agents for the treatment of prostate cancer.
Darolutamide, enzalutamide (Xtandi), and apalutamide (Erleada) have all demonstrated promising findings, signifying that therapies are moving forward in this space. It is exciting to see that patients now have a lot of options, Fleming says.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
2
Cost-Effectiveness of Perioperative Pembro in Head and Neck Cancer Hinges on PD-L1 Expression
3
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
4
FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs
5
































